Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014
Tabakin AL, Shinder BM, Kim S, Rivera-Nunez Z, Polotti CF, Modi PK, Sterling JA, Farber NJ, Radadia KD, Parikh RR, Kim IY, Saraiya B, Mayer TM, Singer EA, Jang TL. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clinical Genitourinary Cancer 2019, 18: e194-e201. PMID: 31818649, DOI: 10.1016/j.clgc.2019.10.018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultFollow-Up StudiesHumansKaplan-Meier EstimateLymph Node ExcisionLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrchiectomyRegistriesRetroperitoneal SpaceRetrospective StudiesSeminomaSurvival RateTesticular NeoplasmsTestisTreatment OutcomeUnited StatesYoung AdultConceptsRetroperitoneal lymph node dissectionPrimary retroperitoneal lymph node dissectionLymph node dissectionOverall survivalTesticular seminomaNode dissectionRole of RPLNDTesticular nonseminomatous germ cell tumorsNational Cancer Data BaseNonseminomatous germ cell tumorsPrimary testicular cancerFive-year OSFirst-line treatmentKaplan-Meier methodOngoing prospective trialsGerm cell tumorsIIB diseaseOS ratesPrimary chemotherapyPrimary therapyProspective trialFinal cohortStage IIATumor histologyClinical stageSurvival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma.
Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionOverall survival rateTesticular seminomaSurvival rateOverall survivalClinical stagePC settingsUnderwent retroperitoneal lymph node dissectionComprehensive community cancer programsFive-year overall survivalNational Cancer DatabaseCommunity cancer programsFirst-line treatmentLow-volume diseaseLymph node dissectionKaplan-Meier methodSurvival dataAvailable survival dataMajority of menNonseminoma histologyPrior chemotherapyNode dissectionSeminoma patientsFinal cohortOngoing trials